- Home
- ASPC vs CRBP Comparison
ASPC vs CRBP Comparison
Compare ASPC & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPC
- CRBP
- Stock Information
- Founded
- ASPC 2024
- CRBP 2009
- Country
- ASPC Hong Kong
- CRBP United States
- Employees
- ASPC N/A
- CRBP N/A
- Industry
- ASPC
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- ASPC
- CRBP Health Care
- Exchange
- ASPC Nasdaq
- CRBP Nasdaq
- Market Cap
- ASPC 80.9M
- CRBP 73.4M
- IPO Year
- ASPC 2024
- CRBP N/A
- Fundamental
- Price
- ASPC $10.14
- CRBP $7.42
- Analyst Decision
- ASPC
- CRBP Strong Buy
- Analyst Count
- ASPC 0
- CRBP 10
- Target Price
- ASPC N/A
- CRBP $60.89
- AVG Volume (30 Days)
- ASPC 9.6K
- CRBP 169.0K
- Earning Date
- ASPC 01-01-0001
- CRBP 05-13-2025
- Dividend Yield
- ASPC N/A
- CRBP N/A
- EPS Growth
- ASPC N/A
- CRBP N/A
- EPS
- ASPC N/A
- CRBP N/A
- Revenue
- ASPC N/A
- CRBP N/A
- Revenue This Year
- ASPC N/A
- CRBP N/A
- Revenue Next Year
- ASPC N/A
- CRBP $150.00
- P/E Ratio
- ASPC N/A
- CRBP N/A
- Revenue Growth
- ASPC N/A
- CRBP N/A
- 52 Week Low
- ASPC $9.95
- CRBP $4.64
- 52 Week High
- ASPC $10.51
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- ASPC N/A
- CRBP 57.11
- Support Level
- ASPC N/A
- CRBP $6.92
- Resistance Level
- ASPC N/A
- CRBP $8.07
- Average True Range (ATR)
- ASPC 0.00
- CRBP 0.61
- MACD
- ASPC 0.00
- CRBP 0.14
- Stochastic Oscillator
- ASPC 0.00
- CRBP 56.33
About ASPC A SPAC III Acquisition Corp. Class A Ordinary Shares
A SPAC III Acquisition Corp is a blank check company.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.